Management of immune thrombocytopenia: Korean experts recommendation in 2017.
- Author:
Jun Ho JANG
1
;
Ji Yoon KIM
;
Yeung Chul MUN
;
Soo Mee BANG
;
Yeon Jung LIM
;
Dong Yeop SHIN
;
Young Bae CHOI
;
Ho Young YHIM
;
Jong Wook LEE
;
Hoon KOOK
Author Information
- Publication Type:Review
- Keywords: Aplastic Anemia Working Party; ITP; Recommendation; Management
- MeSH: Anemia, Aplastic; Clothing; Consensus; Evidence-Based Practice; Hematology; Humans; Insurance; National Health Programs; Platelet Count; Purpura, Thrombocytopenic, Idiopathic*
- From:Blood Research 2017;52(4):254-263
- CountryRepublic of Korea
- Language:English
- Abstract: Management options for patients with immune thrombocytopenia (ITP) have evolved substantially over the past decades. The American Society of Hematology published a treatment guideline for clinicians referring to the management of ITP in 2011. This evidence-based practice guideline for ITP enables the appropriate treatment of a larger proportion of patients and the maintenance of normal platelet counts. Korean authority operates a unified mandatory national health insurance system. Even though we have a uniform standard guideline enforced by insurance reimbursement, there are several unsolved issues in real practice in ITP treatment. To optimize the management of Korean ITP patients, the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) reviewed the consensus and the Korean data on the clinical practices of ITP therapy. Here, we report a Korean expert recommendation guide for the management of ITP.
